SEARCH THIS WEBSITE
Did you know that high-dose IL-23 inhibitors like risankizumab can maintain complete skin clearance in 40% of severe psoriasis patients a full year after stopping treatment?
“IL-23 inhibitors are unique among biologics, potentially offering long-term remissions by targeting the root cause of psoriasis recurrence.”
– Anthony P. Fernandez, MD, PhD
Key Areas We Will Cover
- The evolving landscape of biologics for moderate to severe psoriasis
- Why IL-23 inhibitors stand out from IL-17 and TNF blockers
- Breakthrough data on high-dose risankizumab and guselkumab
- Potential for preventing psoriatic arthritis progression
- Real-world efficacy and safety profiles in 2025/2026
- How to choose the right biologic with expert guidance
Introduction
Psoriasis affects millions in the UK, often requiring advanced therapies like biologics for moderate to severe cases. As a premier Dermatologist practice, The Skin Care Network stays at the forefront of innovations, including the rising prominence of IL-23 inhibitors. Recent 2025 research highlights their potential superiority through upstream cytokine blockade, offering superior long-term control and remission rates. This guide explores why IL-23 therapies may emerge as the best option, drawing on trials and expert insights to inform your treatment decisions.
Understanding Biologics in Psoriasis Management
Biologics target specific immune pathways driving psoriasis inflammation. Older TNF inhibitors paved the way, followed by IL-17 blockers for rapid clearance, and now IL-23 inhibitors for sustained results.
Key classes include:
- TNF inhibitors (e.g., adalimumab, etanercept)
- IL-17 inhibitors (e.g., secukinumab, ixekizumab, bimekizumab)
- IL-23 inhibitors (e.g., guselkumab, risankizumab, tildrakizumab)
Network meta-analyses confirm IL-23 and IL-17 agents outperform TNF blockers in efficacy, with favourable safety.
Why IL-23 Inhibitors Are Gaining Traction
IL-23 sits upstream in the inflammatory cascade, sustaining pathogenic memory T cells (TRM 17) that trigger psoriasis flares. By blocking IL-23 early, these inhibitors may deplete these cells, leading to prolonged remissions unlike downstream IL-17 blockers.
Experts note IL-23’s role as a “master cytokine,” positioning inhibitors like risankizumab and guselkumab for deeper, lasting control.
Breakthrough Evidence for High-Dose IL-23 Therapy
A 2025 phase 2 trial tested high-dose risankizumab (300-600 mg) in severe psoriasis patients. After just three doses and therapy cessation:
- 60% maintained PASI 90 at week 52
- 40% achieved complete clearance
- Skin biopsies revealed a significant reduction in memory T cells
This supports theories of extended remission, potentially transforming psoriasis from chronic to manageable with intermittent dosing.
IL-23 Inhibitors and Psoriatic Arthritis Prevention
Ongoing studies like the PAMPA trial explore guselkumab’s ability to halt progression to psoriatic arthritis (PsA). While IL-17 blockers excel in treating established PsA, IL-23 agents may prevent onset by addressing skin-driven inflammation earlier.
Observational data suggest biologics reduce PsA risk, with IL-23’s upstream action offering unique preventive potential.
Comparing IL-23 with IL-17 Inhibitors
Both classes achieve high PASI scores, but differences emerge:
- IL-17 inhibitors often provide faster initial clearance
- IL-23 inhibitors excel in long-term durability and remission post-treatment
- Real-world 2025 studies show similar drug survival, but IL-23 linked to broader benefits like metabolic improvements
For pure skin clearance without joint involvement, IL-23 increasingly favoured.
Safety and Real-World Performance
IL-23 inhibitors boast excellent safety, with low infection risks and no new signals in long-term data. 2025 registries confirm high persistence rates, outperforming older biologics.
Conclusion
In 2026, IL-23 inhibitors like risankizumab and guselkumab are poised to lead psoriasis treatment, offering unmatched potential for long remissions through targeted memory cell reduction. Key takeaways: superior durability over IL-17 for skin-focused cases, promising PsA prevention, and strong safety. Early intervention maximises benefits, shifting psoriasis management towards sustained control.
Take Control of Your Psoriasis with The Skin Care Network Today
Ready to explore IL-23 inhibitors or find your optimal biologic? Consult our Dermatologist specialists for a personalised assessment.
📅 Book your consultation at our Barnet clinic
Address: 68-70 Union St, Barnet EN5 4HZ, United Kingdom
Phone: +44 20 8441 1043
Secure your appointment online for expert, compassionate care.
Frequently Asked Questions About IL-23 Inhibitors for Psoriasis
This section tackles common queries on biologics, drawing from 2025/2026 evidence to clarify options and outcomes.
Emerging data suggest yes for long-term skin clearance and remission, especially early use; they edge IL-17 for durability without PsA dominance.
IL-23 acts upstream, potentially depleting recurrence-driving cells for longer remissions; IL-17 offers quicker clearance but may not sustain as well off-treatment.
Ongoing trials like PAMPA indicate potential, though IL-17 remains stronger for active PsA; early IL-23 may halt progression.
Generally mild, including injection-site reactions; excellent long-term safety compared to older biologics.
If seeking sustained clearance or facing flares on other therapies, discuss with a Dermatologist expert for tailored advice.
